SCHEMBL18975178

SCHEMBL18975178

Cc1sc(N(CCC2CCCCC2)Cc2ccc(Cl)cc2)nc1C(=O)NS(=O)(=O)Cc1cccc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
MAPT P10636 1/20 0.36
HTR7 P34969 1/20 0.36
CMKLR1 Q99788 3/20 0.35
S1PR1 P21453 2/20 0.34
CXCR3 P49682 2/20 0.34
THRB P10828 2/20 0.33
TP53 P04637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ACHE P22303 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20530842 0.90 CXCR3 (0.37) HTR7CXCR3MEN1KMT2A
SCHEMBL18975107 0.87 ALDH1A1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18975177 0.87 CMKLR1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18975167 0.84 GAA (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18975170 0.84 CMKLR1 (0.42) MAPTCMKLR1CXCR3THRBTP53
SCHEMBL20530856 0.83 PPARD (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18975171 0.83 CMKLR1 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18974570 0.80 HTR7 (0.35) HTR7CMKLR1
SCHEMBL18974645 0.79 LPAR1 (0.40) HTR7CMKLR1ALDH1A1MEN1KMT2A
SCHEMBL20679960 0.79 HTR7 (0.40) MAPTHTR7ALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3388425-B1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LTD (JP) 2020-08-05 EP disclosed
EP-3388425-B1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LTD (JP) 2020-08-05 EP disclosed
US-10689354-B2 Aminoazole derivative TEIJIN PHARMA LIMITED (JP) 2020-06-23 US disclosed
US-20190031628-A1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2019-01-31 US disclosed
EP-3388425-A1 AMINOAZOLE DERIVATIVE Teijin Pharma Limited (JP) 2018-10-17 EP disclosed
WO-2017099237-A1 AMINOAZOLE DERIVATIVE 帝人ファーマ株式会社 2017-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689354-B2 Aminoazole derivative AR, NR3C2, NR5A1 PSEN1 4523/4885PSEN2 4478/4885APH1B 3853/4885
US-20190031628-A1 AMINOAZOLE DERIVATIVE AR, NR3C2, NR5A1 PSEN1 4523/4885PSEN2 4478/4885APH1B 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.